Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 06, 2018 08:00 ET | Source: Tyme Technologies, Inc.

Tyme and JAF Announce Sarcoma Treatment Collaboration

NEW YORK, April 06, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company, today announced that it is collaborating with The Joseph Ahmed Foundation...
March 29, 2018 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies, Inc. Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018

NEW YORK, March 29, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that it will be featured as a presenting company at the H. C. Wainwright...
March 27, 2018 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Announces First Site Open for its Phase II Trial with SM-88 in Pancreatic Cancer

NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that the first site for the Phase II clinical trial evaluating SM-88...
March 14, 2018 08:00 ET | Source: Tyme Technologies, Inc.

FDA Acceptance of IND for Tyme to Begin Phase II Trial in Pancreatic Cancer

Initial Clinical Sites Expected to Open Over the Coming Weeks NEW YORK, March 14, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that the...
March 08, 2018 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies Announces Closing of Public Offering of Common Stock

NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that, on March 6, 2018, it closed its underwritten public offering of...
March 01, 2018 21:46 ET | Source: Tyme Technologies, Inc.

Tyme Technologies Announces Pricing of its Offering of 9 Million Shares of Common Stock

NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (the “Company”) announced today that it has priced its underwritten public offering of 9 million shares of its...
February 26, 2018 16:01 ET | Source: Tyme Technologies, Inc.

Tyme Technologies Announces Offering of Common Stock

NEW YORK, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (the “Company”), a clinical-stage biotechnology company developing cancer therapeutics, today announced that it had...
February 21, 2018 09:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies Appoints Tommy G. Thompson to Board of Directors

NEW YORK, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced the appointment of former...
February 13, 2018 08:00 ET | Source: Tyme Technologies, Inc.

Tyme to Present at RBC Capital Markets 2018 Global Healthcare Conference

NEW YORK, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that company management will...
February 08, 2018 10:00 ET | Source: Tyme Technologies, Inc.

Tyme Announces Interim Phase II Safety and Efficacy Data for SM-88 in Prostate Cancer at 2018 ASCO Genitourinary Cancers Symposium

92% of Patients Have Maintained Radiographic Progression-Free Survival at a Median of 12 Months Since Biochemical-RecurrenceAll Patients Have Reported Stable Cognitive and Sexual Function on SM-88...